Department of Orthopaedic Research, Genzyme Corporation, Framingham, MA 01701, USA.
Osteoarthritis Cartilage. 2012 Nov;20(11):1336-46. doi: 10.1016/j.joca.2012.07.004. Epub 2012 Jul 15.
OBJECTIVE: To perform a molecular mechanism-based investigation of the chondroprotective potential of hylan G-F 20. METHOD: The effects of hylan G-F 20 on IL-1β-induced glycosaminoglycan (GAG) depletion and matrix metalloproteinase (MMP) expression in bovine and human cartilage explants were evaluated. Three weekly intra-articular hylan G-F 20 or control injections were administered 4 weeks post-operatively to rabbits with surgically induced osteoarthritis (OA). Cartilage histopathologic scores and osteophyte size were evaluated at 1, 4, and 8 weeks post-injections. Histomorphometry and immunostaining were used to quantify cartilage area and type II collagen (Col II) intensity, and real-time polymerase chain reaction (PCR) was used to examine the mRNA levels of Col2A1, MMP-13, -16 and IL-1β at 1 week. RESULTS: Hylan G-F 20 retained GAG in IL-1β-exposed bovine and human cartilage explants and abrogated IL-1β-mediated increases in MMP-1, -3, and -13 in human explant culture. Hylan G-F 20‒treated OA joints had significantly better cartilage integrity at 1 and 4 weeks post-treatment and significantly smaller osteophytes at 4 weeks compared with control. Col2A1 mRNA increased with hylan G-F 20 treatment, which correlated with a trend toward increased Col II immunostaining. MMP-13 and -16 mRNAs increased in OA cartilage, but were not significantly altered by hylan G-F 20. IL-1β mRNA was undetectable in cartilage and unaltered in the synovium. CONCLUSIONS: Hylan G-F 20 improved cartilage integrity and decreased osteophyte formation in the rabbit model of OA. Our results suggest that hylan G-F 20 may stimulate cartilage repair by increasing Col II, and inhibit IL-1β-mediated matrix degradation by decreasing MMPs.
目的:基于分子机制研究透明质酸 G-F 20 的软骨保护潜力。
方法:评估透明质酸 G-F 20 对牛和人软骨外植体中白细胞介素 1β(IL-1β)诱导的糖胺聚糖(GAG)耗竭和基质金属蛋白酶(MMP)表达的影响。手术后 4 周,每周向手术诱导骨关节炎(OA)的兔关节内注射 3 次透明质酸 G-F 20 或对照剂。在注射后 1、4 和 8 周评估软骨组织病理评分和骨赘大小。使用组织形态计量学和免疫染色来量化软骨面积和 II 型胶原(Col II)强度,并使用实时聚合酶链反应(PCR)在 1 周时检测 Col2A1、MMP-13、-16 和 IL-1β 的 mRNA 水平。
结果:透明质酸 G-F 20 在 IL-1β 暴露的牛和人软骨外植体中保留了 GAG,并阻断了人外植体培养中 IL-1β 介导的 MMP-1、-3 和 -13 的增加。与对照组相比,透明质酸 G-F 20 治疗的 OA 关节在治疗后 1 周和 4 周时具有更好的软骨完整性,4 周时具有更小的骨赘。Col2A1 mRNA 随着透明质酸 G-F 20 的治疗而增加,这与 Col II 免疫染色的趋势一致。OA 软骨中的 MMP-13 和 -16 mRNA 增加,但透明质酸 G-F 20 没有显著改变。软骨中未检测到 IL-1β mRNA,滑膜中也未改变。
结论:透明质酸 G-F 20 改善了兔 OA 模型的软骨完整性并减少了骨赘形成。我们的结果表明,透明质酸 G-F 20 可能通过增加 Col II 刺激软骨修复,并通过减少 MMP 抑制 IL-1β 介导的基质降解。
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009-12
Int J Oral Maxillofac Surg. 2011-9-1
Arthritis Rheumatol. 2014-5
Biochem Biophys Res Commun. 2018-2-21
BMC Musculoskelet Disord. 2016-4-27
Osteoarthritis Cartilage. 2006-8
J Maxillofac Oral Surg. 2023-12
Arthritis Res Ther. 2017-11-10
Ther Adv Musculoskelet Dis. 2017-9
Drug Deliv Transl Res. 2017-2
Clin Med Insights Arthritis Musculoskelet Disord. 2016-11-22